Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of methotrexate on the dose–effect relationship of infliximab in ankylosing spondylitis
2006-005157-29Phase 4Active
- Sponsor
- CHRU Tours
- Start
- Apr 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of infliximab and methotrexate in ankylosing spondylitis (AS) (2 arms), sponsored by CHRU Tours. Primary endpoints: ASAS20 response at week 12 and Influence of methotrexate on infliximab pharmacokinetics. Started Apr 2007; status: active.
02
Drugs
infliximabmethotrexate
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2006-005157-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005157-29.